Risk factors and Prevalence of Osteoporosis amidst Postmenopausal females turning up the Diabetes and Endocrinology clinic at Azadi Teaching Hospital at Kirkuk /Iraq

Dr. Ali Akram Ismael M.B.Ch.B., F.I.C.M.S., C.A.B.M., D.M., consultant of internal medicine (Kirkuk General Hospital- department of medicine)
Dr. Zahraa G. Abdullah M.B.Ch.B, H.D.F.M. (Tariq Baghdad family medicine center)
Dr. Aydin Othman Aydin M.B.Ch.B.

Abstract: for estimation the prevalence of osteoporosis and osteopenia amidst Iraqi postmenopausal females turning up the Azadi Teaching Hospital's Diabetes and Endocrinology clinic, as well as the relevant venture agents. A descriptive cross-sectional treatise was carried out in a diabetic and endocrinology clinic in Kirkuk, Iraq. An aggregate of 1085 Iraqi postmenopausal females at age 45 to 84 years old were enrolled in this study, which took place between April 2019 and April 2021. The bone mineral density of all patients was measured using a dual-energy X-ray absorptiometry (DEXA) scan. According to World Health Organization recommendations, the DEXA scan was explicated in idioms of T score. Osteoporosis and osteopenia were found to be prevalent in 37.5 percent and 44.6 percent of the population, respectively. The lumbar spine had the highest incidence of osteoporosis (32.40 %), chased via the left femoral neck (14.40 %), and the left femoral neck had the highest frequency of osteopenia (56.10 %), the lumbar spine (41.30 %). Extended menopausal scope, ordinary or overweight BMI, elevated parity, corporal inactivity, affirmative family history of osteoporosis, inconvenient sun exposition, elevated diurnal cafe utilization, low diurnal utilization of calcium, with delayed menarche age were whole linked to osteoporosis. Females with type 2 diabetes, on the other hand, had a decreased incidence of osteoporosis. Iraqi postmenopausal females have a significant frequency of osteoporosis and osteopenia. More generic instruction plus a better publicizing of knowledge about osteoporosis and its prohibition are required.

Key word: Kirkuk; prevalence; osteoporosis and osteopenia; venture agents; type 2 diabetes mellitus

Introduction

Each year, osteoporosis gives rise to more than 8.9 million fractures internationally, with an osteoporotic fracture occurring each three seconds. [1] females are at an increased venture of developing osteoporosis, which affects an estimated 200 million females globally.[2] Shilbayeh [3] discovered that the universal percentage of osteoporosis amidst females in Jordan was 30% regardless of menopausal state, and 43.30 percent amidst postmenopausal females. Furthermore, found that the prevalence of osteoporosis was 13.50% with running age amidst a pattern of Jordanian females divert to investigations about osteoporosis; hypertension, diabetes mellitus, and renal problems plus age at menarche, were each historically correlated with an acceleration of venture of osteoporosis. [4] During their lifetime, half of each postmenopausal females will suffer an osteoporotic-associated fractures, 25% of these females will develop a vertebral disfigurement, and 15% will suffer from a fracture of hip . [5] females account for about 75% of all hip fractures, which are stationary accompanied with disability, persistent pain, decreased motility, increased reliance, and the risk of subsequent fractures. Furthermore, hip fractures caused by osteoporosis are linked to an increased risk of death. The mortality rate after fracture

of hip is as high as 20-25% in the first year. Female genus, age, ethnicity, fumigation, family history of osteoporosis, deficiency of vitamin D, slash calcium ingestion and high caffeine intake, immobility and sedentary life style, raised age at menarche, premature menopause, and underweight (BMI is low) are all venture agents for osteoporosis. [7,8] the relation between osteoporosis and Diabetes mellitus is complicated. Type one diabetes mellitus (T1DM) is a type of diabetes that affects people of all ages.

Slash bone mineral density (BMD) is caused by poor amounts of IGF-1 and insulin in the blood, and it commonly take places in young children before they reach their maximal bone mass. While type 2 diabetes mellitus (T2DM) is common in adults who have already reached their peak bone mass, the impact of T2DM on BMD is debatable; it could be accelerated, decelerated, or remained unchanged. [9,10]. The treatise's Objectives: For estimation the prevalence of osteoporosis and osteopenia amidst postmenopausal females turning up a Diabetes and Endocrinology clinic, as well as the potential venture agents associated with them.

Materials and Procedures:

Data collecting and sampling: A cross-sectional treatise was conducted in the clinic for diabetes and endocrinology at Azadi Teaching Hospital in Kirkuk, Iraq, between April 2020 and April 2021. All women over the age of 45 years, who had been menopausal for more than a year and had their BMD measured by dual-energy X-ray absorptiometry (DEXA) at our facility throughout the treatise duration, were qualified to debate. Patients with T1DM, malignancy, uncontrolled hypothyroidism, hyperthyroidism, primary or secondary hyperparathyroidism, rheumatoid arthritis, systemic lupus erythromatosis(SLE), epilepsy, renal failure, Cushing syndrome, cirrhosis, and premature menopause (45 years old), or patients on one or more of the following drugs: warfarin, heparin and thiazolidinedione.

The patient's medical record and a constitutional oppositional questionnaire conducted over the direct interview. In addition, The medical file was utilized to compile datum on actual age at estimation of BMD, marital state, instructional level, menopause interval, age at menopause and menarche starting, parity, figure of abortions and pregnancies, breast feeding, years of menstruation, diabetes situation and interval, hypertension situation and utilizing of vitamin D3 addendum or Statin, height and weight.

Considerations of morality: The ethical committee of Azadi Teaching Hospital's Diabetic and Endocrinology Clinic accepted the study protocol. Through phone calls and verbal exchanges Patients gave their assent after being told that their data would be kept private and used only for scientific study.

The treatise variables' definitions: Analyses in the lab and measurements The quotient of weight (kg) and height squared was used to calculate the body mass index (BMI) (m2). Patients were categorized. According to BMI, the American Diabetes Association (ADA) approved the World Health Organization's (WHO) recommendation (ADA).(11)

Smoking was prohibited: According to WHO standards from 1998, there are three categories: a current smoker is someone who smokes cigarettes on a daily or irregular basis. Nonsmoker: a person who has never fumigated or has fumigated very slight at the former; past-smoker: a

person who used to smoke diurnally or sometime but no longer does; and past-smoker: a personage who used to smoke diurnal or occasionally but no longer does.(12)

Corporal activity was defined as "the leisure time spent doing any type of moderate-intensity aerobic physical exercise for at least thirteen minutes five days a week." "Immobilization" was described as "I've been in bed for more than two months." or "being restricted to a single position." (14)

According to the ADA 2014, pre-diabetes and diabetes were diagnosed. Furthermore, diabetes was considered controlled if the patient's HbA1c was less than 7.0 percent, moderately controlled if the HbA1c was between 7 and 7.9%, and uncontrolled if the HbA1c was greater than 8%. In adults, sun exposure was described as "daily exposure of the face, arms and hands to the sun for 10–15 minutes (denudation and wanting sun screen)". 15 Caffeine utilization was calculated as the mean diurnal consumption of tea, coffee, caffeinated soft drinks, ice coffee and chocolate at a lifetime. There are various sorts of coffee, including instant, brewed, and Turkish coffee. Each cup (8 oz. of brewed coffee has 85mg caffeine), (8 oz. of instant coffee contains 75mg caffeine), (8 oz. of brewed tea contains 40mg caffeine), and the caffeine content was approximated in milligrams per day depend on numbers from the International Food Information Council Foundation Review16 (12 oz. of cola contains 40mg caffeine). The average amount of caffeine in a cup of Turkish coffee (40 mL) is 165 mg. At the time of data analysis, 17 lifetime daily caffeine intake was categorized into two groups: 0, low caffeine intake (£300mg/day), and 1, high caffeine intake (>300mg/day). 18

Via deducting the age at menopause from the running age at BMD assessment, the duration of menopause was determined. The number of years of menstruation was determined as follows: the age variation between menopause and menarche in years. DEXA (Hologic Discovery A Scanner) was used to evaluate BMD at the lumbar spine L1–L4 (anterior– posterior projection) and left femoral neck, and the results were represented as g/cm2. Only the value of T-score was used for evaluation, as indicated by the WHO diagnostic classification19, which divided the patients into three groups: normal BMD was defined as (T-score at or above 1.0), osteopenia (poor bone mass) as (T-score between 1.0 and 2.5), and osteoporosis as (T-score at -2.5 or less). Vitamin D3 concentrations in the blood were measured using a radioimmunoassay (BIOSOURCE Europe S.A., Nivelles, Belgium) and were divided into three categories: vitamin D deficiency (>20 ng/mL), vitamin D insufficiency (20–29 ng/mL), and vitamin D adequate (30 ng/mL). 2

Analytical statistics: The Statistical Program for Social Sciences (SPSS) version 20.0 was used to analyze the data. Data was checked for data entry mistakes and outlier values, and any problems were fixed as needed. The prevalence of osteoporosis in the general population was determined. The Chi-square test and the t-test were used to analyze the statistical significance of the bivariate correlation between osteoporosis and a variety of factors. A statistically significant p value of 0.05 was used.

Results: Characteristics of Participants The participants in treatise were 1085 postmenopausal females between the ages of 45 and 85, with a mean age (standard deviation) of 61.1 (7.2). Family history of fragility fractures and osteoporosis, perior personal fragility fractures, lifestyle, and other sociodemographic, reproductive, and clinical characteristics, as well as

sociodemographic, reproductive, and clinical characteristics, sociodemographic, reproductive, and clinical characteristics, sociodemographic, reproductive, and clinical characteristics.

Table 1 shows the frequency distribution of the treatise pattern via sociodemograghic, clinical, lifestyle, reproductive, and laboratory characteristics, as well as health (Personal History of Previous Fracture, , Family History of Fragility Fracture, and Family History of Osteoporosis).

variable	Number (9/)
variable	Number (%)
running age at BMD (years)	401 (45 20)
>/= 60	491 (45.20) 594 (54.80)
Matrimonial state	374 (34.60)
celibate	88 (8.00)
wedded	976 (90.30)
Divorced or widowed	21 (1.80)
Instructional level	21 (1.00)
Basic instruction	299 (27.50)
Intermediate instruction	223 (20.50)
Advanced instruction	563 (52.00)
BMI(kg/m ²)	(-2.00)
Normal	98 (8.70)
Overweight	325 (29.70
obese	662 (61.60)
fumigation	
not fumigate	925 (85.40)
running fumigate	160 (14.60)
Corporal activity	
yes	436 (40.10)
no	649 (59.90)
Exposition to sun	
yes	515 (47.50)
no	570 (52.50)
710 (1 7)	
Life time diurnal caffeine(mg/day)	-40 (47 -0)
=300</td <td>518 (47.70)</td>	518 (47.70)
>300	567 (52.30)
Ingestion of calicium	225 (20.00)
600-1000	335 (30.90)
>1000	478 (4.10) 272 (25.00)
	272 (23.00)
Presence of diabetes mellitus	
No DM	147 (14.40)
Pre-DM	406 (37.70)
DM	532 (49.10)
Duration of diabetes Mellitus	
<5 years	176 (34.7)
5-9 years	131 (25.70)
>/=10 years	201 (39.60)
Statin utilization	
yes	736 (67.90)
no	349 (32.10)
D	
Presence of hypertension	(0)(((4.10)
yes	696 (64.10) 389 (35.80)
no	307 (33.00)
Vitamin D3 usage	
Yes Yes	967 (89.30)
no	118 (10.70)
	110 (10.70)
solidification	
yes	31 (2.60)
no	1054 (97.40)
HbA1c	242 (40.20)
Good Controlled(<7)	262 (49.30)
Fairly controlled(7-7.9)	142 (26.60)

Poor controlled(>/=8)	129 (24.10)
Parathyroid hormone(pg/ml)	, ,
=55</td <td>515 (66.30)</td>	515 (66.30)
>55	263 (33.70)
Vitamin D3 level(ng/ml)	
Normal (>/=30)	695 (61.80)
Insufficiency (20-29)	185 (18.1)
Deficiency (<20)	205 (20.10)
Age at menopause (years)	
=50</td <td>670 (61.80)</td>	670 (61.80)
>50	415 (38.20)
Menopausal duration when DXA curried out	
=5 years</td <td>285 (26.20)</td>	285 (26.20)
6-10 years	270 (24.80)
>/=11 years	530 (48.90)
Age at menarche (year)	Mean+/-SD=13.71+/-1.58
Years of menstruation	Mean+/-SD=36.12=+/-3.58
Number of Parity	
=2</td <td>212 (19.50)</td>	212 (19.50)
3-5	466 (43.00)
>/=6	407 (37.50)
Number of Abortion	
None	540 (49.90)
1-2	420 (38.70)
3 &more	125 (11.40)
Breast feeding	
yes	857 (79.10)
no	228 (20.90)
Family history of osteoporosis	
negative	742 (68.50)
positive	343 (31.50)
Family history of fragility fracture	
negative	820 (75.70)
positive	265 (24.30)
Individual history previous fragility fracture	
Negative	877 (81.00)
positive	208 (19.00)

table 2 shows that 32.40% of the entrants had osteoporosis of lumber spine, put up with the left femoral neck (14.40%), while the prevalence of osteopenia was notified high at the left femoral neck (56.10%) put up with the lumbar spine (41.30%).

Table 2. Prevalence of Osteopenia and Osteoporosis Amidst Postmenopausal females (No. 1085)

	Normal (%)	Osteopenia (%)	Osteoporosis (%)
Total	17.89	44.58	37.53
Lumbar spine	26.2	41.3	32.4
Femoral neck	29.6	56.1	14.4

Chi-square distribution was utilized to evaluate the loose distribution of osteoporosis by particular treatise variables. As signalized in Table 3.

Table 3. Chi-Square Distribution and degree of prominence of Osteoporosis via special sociodemographic and Health mutable (number = 1085)

variable	Normal no. (%)	Osteoporosis no. (%)	P value
running age at BMD (years)			0.000
<60	343 (69.9)	149 (30.1)	
>/= 60	334 (56.3)	259 (43.7)	
Marital status			0.002

Single	42 (47.7)	46 (52.3)	
Married	626 (64.2)	350 (35.8)	
Divorced or widowed	9 (42.1)	12 (57.9)	
instruction			0.089
<secondary school<="" td=""><td>171 (57.2)</td><td>128 (42.8)</td><td></td></secondary>	171 (57.2)	128 (42.8)	
secondary school	142 (63.8)	81 (36.2)	
>secondary school	364 (64.6)	199 (35.3)	
BMI (kg/m²)			0.000
Normal	43 (44.7)	53 (55.3)	
Over weight	167 (51.7)	156 (48.3)	
obese	462 (70.1)	197 (29.9)	
Smoking			0.261
Never smoke	582 (62.9)	344 (37.1)	
Current smoke	95 (59.9)	64 (40.1)	
Physical activity			0.000
No	369 (56.8)	281 (43.2)	
yes	309 (70.9)	128 (29.1)	
Sun exposure	(***)		0.000
No	323 (56.6)	248 (43.4)	0.000
yes	354 (68.9)	160 (31.1)	
Life time diurnal caffeine(mg/day)			0.015
=300</td <td>433 (66.2)</td> <td>175 (33.8)</td> <td></td>	433 (66.2)	175 (33.8)	
>300	334 (59)	232 (41)	
Ingestion of calicium			0.013
<600	188 (56.2)	147 (43.8)	
600-1000	307 (64.3)	171 (35.7)	
>1000	182 (67.0)	90 (33.0)	
Diabetic status			0.003
No	76 (51.7)	61 (48.3)	
Pre-DM	247 (60.9)	159 (39.1)	
DM	354 (66.6)	178 (33.4)	
Duration of diabetes (years)			0.045
<5	130 (74.1)	46 (25.9)	
	<u> </u>		

x/=10 125 (62.3) 76 (37.7) 0.337 use of statin 0.337 0.337 no 211 (60.4) 139 (39.6) 0.295 yes 466 (63.4) 269 (36.6) 0.295 Hypertension 235 (60.4) 155 (39.6) 0.295 yes 466 (63.4) 253 (36.6) 0.325 Use of vitamin D3 0.325 0.325 0.325 No 69 (58.3) 50 (41.7) 0.556 No 660 (62.6) 395 (37.4) 0.556 No 660 (62.6) 395 (37.4) 0.556 HbA1c 30 (60.2) 395 (37.4) 0.403 Good Controlled (<7) 131 (66.5) 88 (33.5) 0.403 Fairly controlled (<7-9) 91 (70.0) 43 (30.0) 0.038 <-55 327 (63.5) 189 (36.5) 0.038 <-55 327 (63.5) 189 (36.5) 0.038 <-55 327 (63.5) 189 (36.5) 0.008 Vitamin D3 level(ng/ml) 0.008 0.008 0.008 Normal (>=0.29) 117 (63.4) 68 (36.6) 0.009	5-9	85 (65.1)	46 (34.9)	
no yes	>/=10	125 (62.3)	76 (37.7)	
Yes 466 (63.4) 269 (36.6)	use of statin			0.337
Hypertension	no	211 (60.4)	139 (39.6)	
No yes 466 (63.4) 155 (39.6) yes 466 (63.4) 155 (39.6) 253 (36.6) 0.325 No 69 (58.3) So (41.7) yes 608 (63.0) 358 (37.0) Immobilization No 660 (62.6) 395 (37.4) yes 17 (57.1) 13 (42.9) HbA1c Good Controlled(<7) 131 (66.5) 88 (33.5) Fairly controlled(>7-9) 91 (70.0) 43 (30.0) Poorly controlled(>7-8) Parathyroid hormone(pg/ml) =55 327 (63.5) 189 (36.5) 55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) Normal (>/=30) 1nsufficiency (20-29) 117 (63.4) Age at menopause (years) =50 412 (61.5) 259 (38.5) ≥50 Menopausal duration at time of DXA performing </=5 6-10 167 (61.9) 103 (38.1) /=11 280 (56.2) 232 (43.8)	yes	466 (63.4)	269 (36.6)	
yes 466 (63.4) 253 (36.6) 0.325 No 69 (58.3) 50 (41.7) 0.325 yes 608 (63.0) 358 (37.0) 0.556 Immobilization 0.556 0.556 No 660 (62.6) 395 (37.4) 0.556 yes 17 (57.1) 13 (42.9) 0.403 HbA1c 131 (66.5) 88 (33.5) 88 (33.5) 0.403 Good Controlled(91 (70.0) 43 (30.0) 0.003 Poorly controlled(>=8) 80 (62.2) 49 (37.8) 0.038 <=55	Hypertension			0.295
Use of vitamin D3 No 69 (58.3) 50 (41.7) yes 608 (63.0) 358 (37.0) Immobilization No 9 (608 (63.0) 358 (37.0) Immobilization No 9 (608 (63.0) 358 (37.0) Immobilization No 9 (600 (62.6) 395 (37.4) yes 17 (57.1) 13 (42.9) Immobilization No 9 (600 (62.6) 395 (37.4) yes 17 (57.1) 13 (42.9) Immobilization Immobilization No 9 (600 (62.6) 395 (37.4) yes 13 (66.5) 88 (33.5) Fairly controlled(<7) Fairly controlled(<7.9) 91 (70.0) 43 (30.0) Poorly controlled(>=8) Parathyroid hormone(pg/ml) 2 (55 327 (63.5) 189 (36.5) >>55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) Normal (> -30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20) Age at menopause (years) 412 (61.5) 259 (38.5) >>0 Menopausal duration at time of DXA performing <	No	235 (60.4)	155 (39.6)	
No 69 (58.3) 50 (41.7) yes 608 (63.0) 358 (37.0) Immobilization 0.556 No 660 (62.6) 395 (37.4) yes 17 (57.1) 13 (42.9) HbA1c 0.403 Good Controlled(<7)	yes	466 (63.4)	253 (36.6)	
yes 608 (63.0) 358 (37.0) 0.556 Immobilization 0.556 No 660 (62.6) 395 (37.4) 0.556 yes 17 (57.1) 13 (42.9) 0.403 HbA1c 131 (66.5) 88 (33.5) 0.403 Good Controlled(91 (70.0) 43 (30.0) 43 (30.0) Poorly controlled(80 (62.2) 49 (37.8) 0.038 2=55 327 (63.5) 189 (36.5) 0.038 >55 146 (55.8) 116 (44.2) 0.279 Vitamin D3 level(ng/ml) 378 (60.4) 248 (39.6) 0.279 Normal (>/=30) 378 (60.4) 248 (39.6) 0.279 Deficiency (<20)	Use of vitamin D3			0.325
Immobilization	No	69 (58.3)	50 (41.7)	
No 660 (62.6) 395 (37.4) yes 17 (57.1) 13 (42.9) HbA1c (Good Controlled(<7)	yes	608 (63.0)	358 (37.0)	
yes 17 (57.1) 13 (42.9) HbA1c 0.403 Good Controlled(131 (66.5) 88 (33.5) Fairly controlled(>7-9) 91 (70.0) 43 (30.0) Poorly controlled(>/=8) 80 (62.2) 49 (37.8) Parathyroid hormone(pg/ml) 0.038 2=55 327 (63.5) 189 (36.5) >55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) 378 (60.4) 248 (39.6) Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	Immobilization			0.556
HbA1c Good Controlled(<7) Fairly controlled(7-7.9) Poorly controlled(√-8) Parathyroid hormone(pg/ml) <	No	660 (62.6)	395 (37.4)	
Good Controlled(131 (66.5) 88 (33.5) Fairly controlled(7-7.9) 91 (70.0) 43 (30.0) Poorly controlled(>/=8) 80 (62.2) 49 (37.8) Parathyroid hormone(pg/ml) 0.038 =55</td 327 (63.5) 189 (36.5) >55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) 0.279 Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	yes	17 (57.1)	13 (42.9)	
Fairly controlled(7-7.9) Poorly controlled(>/=8) 80 (62.2) 49 (37.8) 0.038 Parathyroid hormone(pg/ml) \$\left(= \frac{1}{2} \) \$\left(= \frac{1}{	HbA1c			0.403
Poorly controlled(>/=8) 80 (62.2) 49 (37.8) 0.038 Parathyroid hormone(pg/ml) 0.038 0.038 2=55 327 (63.5) 189 (36.5) 189 (36.5) >55 146 (55.8) 116 (44.2) 0.279 Vitamin D3 level(ng/ml) 378 (60.4) 248 (39.6) 0.279 Normal (>/=30) 117 (63.4) 68 (36.6) 68 (36.6) Deficiency (20-29) 117 (63.4) 68 (36.6) 69 (33.5) Age at menopause (years) 412 (61.5) 259 (38.5) 0.390 >50 265 (64.1) 149 (35.9) 0.000 Menopausal duration at time of DXA performing 212 (74.6) 73 (25.4) 0.000 -50 167 (61.9) 103 (38.1) 10.000 >=5 212 (74.6) 73 (25.4) 10.000 -10 167 (61.9) 103 (38.1) 10.000 -11 280 (56.2) 232 (43.8) 10.000	Good Controlled(<7)	131 (66.5)	88 (33.5)	
Parathyroid hormone(pg/ml) 0.038 =55</td 327 (63.5) 189 (36.5) >55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) 0.279 Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	Fairly controlled(7-7.9)	91 (70.0)	43 (30.0)	
=55</td 327 (63.5) 189 (36.5) >55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) 0.279 Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	Poorly controlled(>/=8)	80 (62.2)	49 (37.8)	
>55 146 (55.8) 116 (44.2) Vitamin D3 level(ng/ml) 0.279 Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	Parathyroid hormone(pg/ml)			0.038
Vitamin D3 level(ng/ml) 0.279 Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	=55</td <td>327 (63.5)</td> <td>189 (36.5)</td> <td></td>	327 (63.5)	189 (36.5)	
Normal (>/=30) 378 (60.4) 248 (39.6) Insufficiency (20-29) 117 (63.4) 68 (36.6) Deficiency (<20)	>55	146 (55.8)	116 (44.2)	
Insufficiency (20-29) Deficiency (<20) 136 (66.5) Age at menopause (years) =50 412 (61.5) 259 (38.5) 50 Menopausal duration at time of DXA performing =5 212 (74.6) 73 (25.4) 6-10 167 (61.9) 103 (38.1) /=11 280 (56.2) 232 (43.8)	Vitamin D3 level(ng/ml)			0.279
Deficiency (<20)	Normal (>/=30)	378 (60.4)	248 (39.6)	
Age at menopause (years) 0.390 =50</td 412 (61.5) 259 (38.5) >50 265 (64.1) 149 (35.9) Menopausal duration at time of DXA performing 0.000 =5</td 212 (74.6) 73 (25.4) 6-10 167 (61.9) 103 (38.1) >/=11 280 (56.2) 232 (43.8)	Insufficiency (20-29)	117 (63.4)	68 (36.6)	
=50</td 412 (61.5) 259 (38.5) >50 265 (64.1) 149 (35.9) Menopausal duration at time of DXA performing 0.000 =5</td 212 (74.6) 73 (25.4) 6-10 167 (61.9) 103 (38.1) >/=11 280 (56.2) 232 (43.8)	Deficiency (<20)	136 (66.5)	69 (33.5)	
>50 265 (64.1) 149 (35.9) Menopausal duration at time of DXA performing 0.000 =5</td 212 (74.6) 73 (25.4) 6-10 167 (61.9) 103 (38.1) >/=11 280 (56.2) 232 (43.8)	Age at menopause (years)			0.390
Menopausal duration at time of DXA performing 0.000 =5</td 212 (74.6) 73 (25.4) 6-10 167 (61.9) 103 (38.1) >/=11 280 (56.2) 232 (43.8)	=50</td <td>412 (61.5)</td> <td>259 (38.5)</td> <td></td>	412 (61.5)	259 (38.5)	
=5</td 212 (74.6) 73 (25.4) 6-10 167 (61.9) 103 (38.1) >/=11 280 (56.2) 232 (43.8)	>50	265 (64.1)	149 (35.9)	
6-10 167 (61.9) 103 (38.1) >/=11 280 (56.2) 232 (43.8)	Menopausal duration at time of DXA performing			0.000
>/=11 280 (56.2) 232 (43.8)	=5</td <td>212 (74.6)</td> <td>73 (25.4)</td> <td></td>	212 (74.6)	73 (25.4)	
	6-10	167 (61.9)	103 (38.1)	
Parity 0.052	>/=11	280 (56.2)	232 (43.8)	
	Parity			0.052

=2</td <td>126 (59.5)</td> <td>86 (40.5)</td> <td></td>	126 (59.5)	86 (40.5)	
3-5	310 (66.6)	156 (33.4)	
>/=6	241 (59.3)	166 (40.7)	
Abortion			0.752
None	343 (63.6)	197 (36.4)	
1-2	257 (61.2)	163 (38.8)	
3 &more	77 (61.8)	48 (38.2)	
Breast feeding			0.186
No	134 (58.7)	95 (41.3)	
yes	543 (63.5)	313 (36.5)	
Family history of osteoporosis			0.000
No	494 (66.6)	249 (33.4)	
yes	183 (53.5)	159 (46.5)	
Family history of fragility fracture			0.000
No	540 (65.9)	281 (34.1)	
yes	137 (51.9)	127 (48.1)	
Personal of perior fragility fracture			0.001
No	569 (64.9)	309 (35.1)	
yes	108 (52.2)	99 (47.8)	
		l .	1

Discussion

The prevalence of osteoporosis amidst postmenopausal females coming a diabetes and Endocrinology visiting clinic was 37.50% in this treatise. This result was greater than the 16.20% prevalence average recorded in Turkey[21], which was equivalent to the 37.80 % prevalence rate reported in India[22], but less than the 44.10% prevalence average informed at kingdom of Saudi Arabia. [23] This discrepancy in the results could be due to variation in treatise pattern, techniques of diagnosis, bone scan area selection, lifestyle pursuit, and patient election. Non diabetics and pre-diabetics had a more chance for achiving osteoporosis than type 2 diabetic patients, according to our findings. This conclusion was in line with the findings of numerous research[24-26], but not with the findings of other investigations. [27,28] Even after controlling for other variables, this study found that the number of years since menopause was an important predictor in predicting osteoporosis. This result was consistent with what has been published in the academic literature. [21,29,30] Our research discovered a link between the age at menarche and the likelihood of getting osteoporosis. Because premature menarche is associated with increased revolving estrogen pending and after menarche, it may protect against the development of osteoporosis. There was also a link between premature menarche and high BMD. [31,32] while, our results contradicted those of else treatise[33–35], which revealed no

link between menarche age and BMD or fracture venture. Our results showed that increased parity was a venture agent for osteoporosis, which was proportional with the results of else treatises[36,37]. Increased parity, on the other hand, protects postmenopausal women from osteoporosis, according to Sadat-Ali et al. [23] Obesity has a preventive effect against osteoporosis, according to our findings, and a greater BMI may do requite for the unfavorable impact of hypo estrogen on BMD following menopausal period. Some research backed up this conclusion, claiming that a larger body weight correlates with stronger bone density and a decreased risk of fracture. [38,39] plenty theories have been proposed to explicate this relationship, one of which is that a bigger corporal mass places a maximal mechanical pressure on bone, causing bone mass to increase to handle this burden. Also adipocytes are key providers of estrogen in postmenopausal females, and estrogen has been shown to suppress osteoclast bone resorption.so it is observed that raising mass of fat may not have a favorable sequel on bone mass, which contradicts our findings. (40) In our research, postmenopausal women who consumed more than 300 mg of caffeine per day had a higher chance of developing osteoporosis. Rapuri et al. discovered that caffeine intake of >300mg/day accelerated bone loss at the spine in elderly postmenopausal women, which is consistent with our findings. [18], on the other hand, another study was discovered that coffee drinking has a clinically conservative effectiveness on periodontal bone loss. [41] many investigations have shown that cafe affects and osteocytes directly, disrupting their differentiation, mineralization, and bone matrix synthesis, and causing them to perish. [42-45] Caffeine may also accelerate the discrimination of osteoclasts, leading to more calcium lack in the urine. (46) each of these mechanizations could have a role in the loss of bone density induced by excessive coffee use. It is generally understood that appropriate calcium consumption is critical for maintaining bone health during the growing period, plus the protection of BMD in the old females. [49,50] When calcium levels fall, parathyroid hormone rises quickly to compensate, stimulating osteoclast-mediated bone resorption. [51,52] The link between low calcium consumption (600 mg/day) and osteoporosis was headmost of the most significant results in our treatise. In line with our findings, Ensrud et al. found that low fractional calcium absorption combined with inadequate calcium intake increases the risk of hip fracture in elderly women. (53) In our study, postmenopausal patients who did not get enough sun were more likely to progress osteoporosis. However, because the wide number of our patients were taking vitamin D supplements, our study was unable to evaluate the effect of vitamin D insufficiency on osteoporosis. Contrary to our returns, some studies was discovered that a low vitamin D level in postmenopausal females is a prevalent risk factor for osteoporosis. (54, 55) Our research found that insufficient physical activity was linked to accelerate the hazard of osteoporosis, highlighting the prominence of corporal activity in reducing the venture of falls via particular muscle strengthening and balance training actions, which should protect muscle strength, postponed sarcopenia (muscle mass loss with aging), and safeguard neuromuscular activities, all of which are necessary for maintaining balance and a good fall reaction. Physical exercise, that its impact on bone mass, can induce bone production leading to mend BMD by displaying the skeleton to mechanical pressure. Furthermore, one survey discovered a favorable correlation between physical activity and BMD, as well as a protective effect for exercise in BMD. [56] There was no significant link between smoking and osteoporosis in this study. Young et al. similarly flop to discover a substantial link between osteoporosis and smoking, which is consistent with our findings. (57) while two other studies were discovered a link between cigarette use and osteoporosis venture. [58,59] In our study, there was a clear link between having a family history of osteoporosis and the chance of getting osteoporosis. Other studies [60–62] found that having a family history of osteoporosis is an independent risk factor for osteoporosis, similar to our findings.

Conclusion: In Kirkuk, postmenopausal women have a significant prevalence of osteoporosis and osteopenia. More generic instruction and broad transmission of knowledge regarding osteoporosis and its forbidding are required.

Restrictions: are a serious issue. At headmost, that our treatise pattern was recruited from a congregation of postmenopausal females who had been transmitted to DEXA screening during the treatise interval, a method that could lead to selection bias and, as a result, sway the results. while, our insularity gauge, which excluded abundant people with deep-seated conditions and those using drugs that could affect bone density, greatly reduced this effect. Second, while the plurality of information was gathered from the center's medical radiological laboratory records.

Recommendations: More research is needed to increase women's awareness and trainings about osteoporosis and how to avoid it, via particular guidance on proper calcium, cafe, and vitamin D consumption, as well as inducement to engage in rising frequent corporal activity.

There is no conflict of interest between the authors

The study is self funded

References

- 1. Johnell O, Kanis JA. An estimate of the world wide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733.
- 2. Kanis JA. WHO Technical Report, University of Sheffield, United Kingdom, p. 66, 2007.
- 3. Shilbayeh S. Prevalence of osteoporosis and its reproductive risk factors among Jordanian women: a cross-sectional study. Osteoporos Int. 2003;14:929–940.
- 4. El-Heis MA, Al-Kamil EA, Kheirallah KA, et al. Factors associated with osteoporosis among a sample of Jordanian women referred for investigation for osteoporosis/Facteurs associes a l'osteoporose dans un echantillon de femmes Jordaniennes orientees pour un depistage de l'osteoporose. East Mediterr Health J. 2013;19:459.
- 5. Chon KS, Sartoris DJ, Brown SA, et al. Alcoholism-associated spinal and femoral bone loss in abstinent male alcoholics, as measured by dual X-ray absorptiometry. Skeletal Radiol. 1992;21:431–436.
- 6. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol. 2002;16:795.
- 7. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50:1644–1650.
- 8. Abushaikha L, Omran S. A survey of osteoporosis risk factors and practices among Jordanian women. J Int Womens Stud. 2013;11:153–161.
- 9. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: possible cellular and molecular mechanisms. World J Diabetes. 2011;2:41–48.
- 10. Adil C, Aydın T, Tasxpınar O", et al. Bone mineral density evaluation of patients with type 2 diabetes mellitus. J Phys Ther Sci. 2015;27:179.
- 11. American Diabetes Association. Standards of medical care in diabetes 2011. DC 2011;30:S4-S40.
- 12. World Health Organization. Guidelines for Controlling and Monitoring the Tobacco Epidemic. WHO: Geneva, 1998.
- 13. World Health Organization. Global Recommendations on Physical Activity for Health. WHO: Geneva, 2010.

- 14. World Health Organization. Physical Status: The Use and Interpretation of Anthropometry: Report of WHO Expert Committee. WHO: Geneva, 1995.
- 15. International Osteoporosis Foundation (IOF). Sources of Vitamin D, 2008. Available at http://iofbonehealth.org (accessed May 20, 2017).
- 16. International food information council foundation. IFIC Review, Caffeine and health clarifying the controversies, 2014. Available at
- www.foodinsight.org/IFIC_Review_Caffeine_and_Health_Clarifying_the_Controversies (accessed May 20, 2017).
- 17. Afifi S, Rahahleh WA, Hadidi KA. Caffeine content in Turkish coffee: A question of concern in sport community. Dirasat: Educational Sciences. 2008;35:730–738.
- 18. Rapuri P, Gallagher J, Kinyamu H, et al. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr. 2001;74:694–700.
- 19. World Health Organization. Research on the Menopause in the 1990s: Report of a WHO Scientific Group. WHO: Geneva, 1996.
- 20. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281. 21. Demir B, Haberal A, Geyik P, et al. Identification of the risk factors for osteoporosis among postmenopausal women. Maturitas. 2008;60:253–256.
- 22. Waliullah S, Sharma V, Srivastava R, et al. Prevalence of primary post menopausal osteoporosis at various sites in Indian females. Int J Health Sci Res. 2014;4:113–117.
- 23. Sadat-Ali M, Al-Habdan IM, Al-Mulhim AA, et al. Bone mineral density among postmenopausal Saudi women. Saudi Med J. 2004;25:1623–1625.
- 24. Sharifi F, Ahmadimoghadam N, Mousavinasab N. The relationship between type 2 diabetes mellitus and bone density in postmenopausal women. Int J Endocrinol Metab. 2006;4:117–122.
- 25. Anaforoglu I, Nar-Demirer A, Bascil-Tutuncu N, et al. Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. J Diabetes Complications. 2009;23:12–17.
- 26. van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulindependent diabetes mellitus: the Rotterdam Study. Ann Intern Med. 1995;122:409–414. Hyassat, et al.; BioResearch Open Access 2017,
- 6.1 http://online.liebertpub.com/doi/10.1089/biores.2016.0045 92 Downloaded by 87.236.233.142 from online.liebertpub.com at 07/25/17. For personal use only.
- 27. Al-Maatouq MA, El-Desouki MI, Othman SA, et al. Prevalence of osteoporosis among postmenopausal females with diabetes mellitus. Saudi Med J. 2004;25:1423–142.
- 28. Moghimi N, Rahimi E, Derakhshan S, et al. Osteoporosis in postmenopausal diabetic women; prevalence and related factors. Iranian J Nucl Med. 2008;16:28–33.
- 29. Sharami S, Millani M, Alizadeh A, et al. Risk factors of osteoporosis in women over 50 years of age: a population based study in the North of Iran. J Turkish-German Gynecol Assoc. 2008;9:38–44.
- 30. D'Amelio P, Spertino E, Martino F, et al. Prevalence of postmenopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry. Calcif Tissue Int. 2013;92:437–443.
- 31. Ito M, Yamada M, Hayashi K, et al. Relation of early menarche to high bone mineral density. Calcif Tissue Int. 1995;57:11–14.
- 32. Parker SE, Troisi R, Wise LA, et al. Menarche, menopause, years of menstruation, and the incidence of osteoporosis: the influence of prenatal exposure to diethylstilbestrol. J Clin Endocrinol Metab. 2013;99:594–601.
- 33. Gerdhem P, Obrant KJ. Bone mineral density in old age: the influence of age at menarche and menopause. J Bone Min Metab. 2004;22:372–375.
- 34. Sioka C, Fotopoulos A, Georgiou A, et al. Age at menarche, age at menopause and duration of fertility as risk factors for osteoporosis. Climacteric. 2010;13:63–71.
- 35. Paganini-Hill A, Atchison KA, Gornbein JA, et al. Menstrual and reproductive factors and fracture risk: the Leisure World Cohort Study. J Womens Health. 2005;14:808–819.

- 36. Allali F, Maaroufi H, El Aichaoui S, et al. Influence of parity on bone mineral density and peripheral fracture risk in Moroccan postmenopausal women. Maturitas. 2007;57:392–398.
- 37. Gur A, Nas K, Cevik R, et al. Influence of number of pregnancies on bone mineral density in postmenopausal women of different age groups. J Bone Miner Metab. 2003;21:234–241.
- 38. Harris SS, Dawson-Hughes B. Weight, body composition, and bone density in postmenopausal women. Calcif Tissue Int. 1996;59:428–432.
- 39. Pruzansky ME, Turano M, Luckey M, et al. Low body weight as a risk factor for hip fracture in both black and white women. J Orthop Res. 1989;7:192–197.
- 40. Zhao LJ, Liu YJ, Liu PY, et al. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab. 2007;92:1640–1646.
- 41. Ng N, Kaye EK, Garcia RI. Coffee consumption and periodontal disease in males. J Periodontol. 2014;85:1042–1049.
- 42. Su SJ, Chang KL, Su SH, et al. Caffeine regulates osteogenic differentiation and mineralization of primary adipose-derived stem cells and a bone marrow stromal cell line. Int J Food Sci Nutr. 2013;64:429–436.
- 43. Macedo RM, et al. Osteointegration of autogenous bone graft associated with osteoblastic cells under treatment with caffeine. Implant Dent. 2011;20:369–373.
- 44. Lu P-Z, Lai C-Y, Chan W-H. Caffeine induces cell death via activation of apoptotic signal and inactivation of survival signal in human osteoblasts. Int J Mol Sci. 2008;9:698–718.
- 45. Liu SH, et al. Caffeine enhances osteoclast differentiation from bone marrow hematopoietic cells and reduces bone mineral density in growing rats. J Orthop Res. 2011;29:954–960.
- 46. Lacerda SA, Matuoka RI, Macedo RM, et al. Bone quality associated with daily intake of coffee: a biochemical, radiographic and histometric study. Braz Dental J. 2010;21:199–204.
- 47. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. J Bone Miner Res. 1993;8:1–9.
- 48. Ross AC, Taylor CL, Yaktine AL, et al.; Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. DRI, Dietary Reference Intakes: Calcium, Vitamin D. National Academies Press
- (US), Washington, DC, 2011.
- 49. National Institutes of Health (U.S.). Optimal Calcium Intake. National Institutes of Health, Bethesda; pp. 1–31; 1994.
- 50. Shea BJ, Adachi JD, Cranney A, et al. Calcium Supplementation on Bone
- Loss in Postmenopausal Women. The Cochrane Library, 2004.
- 51. Allain TJ, Dhesi J. Hypovitaminosis D in older adults. Gerontology. 2002;49:273–278.
- 52. Parfitt AM, Gallagher JC, Heaney RP, et al. Vitamin D and bone health in the elderly. Am J Clin Nutr. 1982;36:1014–1031.
- 53. Ensrud KE, Duong TU, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med. 2000;132:345–353.
- 54. Gaugris S, Heaney R, Boonen S, et al. Vitamin D inadequacy among postmenopausal women: a systematic review. QJM. 2005;98:667–676.
- 55. Mezquita-Raya P, Mun oz-Torres M, De Dios Luna J, et al. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res. 2001;16:1408–1415.
- 56. Omland LM, Tell GS, Ofjord S, et al. Risk factors for low bone mineral density among a large group of Norwegian women with fractures. Eur J Epidemiol. 2000;16:223–229.
- 57. Young D, Hopper JL, Nowson CA, et al. Determinants of bone mass in 10- to 26-year-old females: a twin study. J Bone Miner Res. 1995;10:558–567.
- 58. Benson BW, Shulman JD. Inclusion of tobacco exposure as a predictive factor for decreased bone mineral content. Nicotine Tob Res. 2005;7: 719–724.

- 59. Krall EA, Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorption. J Bone Miner Res. 1999;14:215–220.
- 60. Seeman E, Hopper JL, Bach LA, et al. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989;320:554–558.
- 61. Soroko SB, Barrett-Connor E, Edelstein SL, et al. Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo Study. J Bone Miner Res. 1994;9:761–769.
- 62. Robitaille J, Yoon PW, Moore CA, et al. Prevalence, family history, and prevention of reported osteoporosis in US women. Am J Prev Med. 2008;35:47–54.